In conclusion, this study demonstrates methylation of the promoter region for gene CADM1, when used in a panel of biomarkers, is a promising candidate for use as part of an anal screening algorithm for HSIL in HRHPV positive GBM. The gene discussed is CADM1; the disease is glioblastoma.